Therefore, a better understanding of the physiological role of TREM2 in microglia regulation and how TREM2 signaling affects tau aggregation and propagation in an amyloid-dependent and independent manner is required before targeting TREM2 as a therapeutic entry point for AD. The gene discussed is TREM2; the disease is amyloidosis.